Literature DB >> 33613119

Advancement and properties of circular RNAs in prostate cancer: An emerging and compelling frontier for discovering.

Hong Zhou1,2,3, Xu-Dong Zheng2,3, Chang-Ming Lin4, Jie Min5, Shuang Hu2,3, Ying Hu2,3, Liang-Yun Li2,3, Jia-Si Chen2,3, Yu-Min Liu2,3, Hao-Dong Li2,3, Xiao-Ming Meng2,3, Jun Li2,3, Ya-Ru Yang6, Tao Xu2,3.   

Abstract

Prostate cancer (PC) is the most common carcinoma among men worldwide which results in 26% of leading causes of cancer-related death. However, the ideal and effective molecular marker remains elusive. CircRNA, initially observed in plant-infected viruses and Sendai virus in 1979, is generated from pre-mRNA back-splicing and comes in to play by adequate expression. The differential expression in prostate tissues compared with the control reveals the promising capacity in modulating processes including carcinogenesis and metastasis. However, the biological mechanisms of regulatory network in PC needs to systemically concluded. In this review, we enlightened the comprehensive studies on the definite mechanisms of circRNAs affecting tumor progression and metastasis. What's more, we validated the potential clinical application of circRNAs serving as diagnostic and prognostic biomarker. The discussion and analysis in circRNAs will broaden our knowledge of the pathogenesis of PC and further optimize the current therapies against different condition. © The author(s).

Entities:  

Keywords:  biomarker; circular RNA; microRNA; prostate cancer (PC); tumorigenesis

Mesh:

Substances:

Year:  2021        PMID: 33613119      PMCID: PMC7893591          DOI: 10.7150/ijbs.52266

Source DB:  PubMed          Journal:  Int J Biol Sci        ISSN: 1449-2288            Impact factor:   6.580


  140 in total

1.  Re: AR-V7 and Resistance to Enzalutamide and Abiraterone in Prostate Cancer.

Authors:  Maxine Sun; Firas Abdollah
Journal:  Eur Urol       Date:  2015-07       Impact factor: 20.096

2.  Molecular processes leading to aberrant androgen receptor signaling and castration resistance in prostate cancer.

Authors:  Rong Hu; Samuel R Denmeade; Jun Luo
Journal:  Expert Rev Endocrinol Metab       Date:  2010-09

3.  Reduction of circular RNA Foxo3 promotes prostate cancer progression and chemoresistance to docetaxel.

Authors:  Zhiyuan Shen; Le Zhou; Chao Zhang; Jun Xu
Journal:  Cancer Lett       Date:  2019-10-05       Impact factor: 8.679

Review 4.  Diabetes in pregnancy: timing and mode of delivery.

Authors:  Gianpaolo Maso; Monica Piccoli; Sara Parolin; Stefano Restaino; Salvatore Alberico
Journal:  Curr Diab Rep       Date:  2014-07       Impact factor: 4.810

5.  Wild-type p53 suppresses the epithelial-mesenchymal transition and stemness in PC-3 prostate cancer cells by modulating miR‑145.

Authors:  Dong Ren; Min Wang; Wei Guo; Xiaohui Zhao; Xiang'an Tu; Shuai Huang; Xuenong Zou; Xinsheng Peng
Journal:  Int J Oncol       Date:  2013-02-12       Impact factor: 5.650

Review 6.  EMT, the cytoskeleton, and cancer cell invasion.

Authors:  Mahmut Yilmaz; Gerhard Christofori
Journal:  Cancer Metastasis Rev       Date:  2009-06       Impact factor: 9.264

7.  Exosome circ_0044516 promotes prostate cancer cell proliferation and metastasis as a potential biomarker.

Authors:  Tian Li; Xiangzhou Sun; Liheng Chen
Journal:  J Cell Biochem       Date:  2019-10-17       Impact factor: 4.429

8.  Androgen receptor signaling in prostate cancer development and progression.

Authors:  Peter E Lonergan; Donald J Tindall
Journal:  J Carcinog       Date:  2011-08-23

9.  Circular RNA circABCC4 as the ceRNA of miR-1182 facilitates prostate cancer progression by promoting FOXP4 expression.

Authors:  Changkun Huang; Huanghao Deng; Yinhuai Wang; Hongyi Jiang; Ran Xu; Xuan Zhu; Zhichao Huang; Xiaokun Zhao
Journal:  J Cell Mol Med       Date:  2019-07-03       Impact factor: 5.310

10.  A Circular RNA Binds To and Activates AKT Phosphorylation and Nuclear Localization Reducing Apoptosis and Enhancing Cardiac Repair.

Authors:  Yan Zeng; William W Du; Yingya Wu; Zhenguo Yang; Faryal Mehwish Awan; Xiangmin Li; Weining Yang; Chao Zhang; Qi Yang; Albert Yee; Yu Chen; Fenghua Yang; Huan Sun; Ren Huang; Albert J Yee; Ren-Ke Li; Zhongkai Wu; Peter H Backx; Burton B Yang
Journal:  Theranostics       Date:  2017-08-29       Impact factor: 11.556

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.